Uncovering Novel Therapeutic Targets In Immune Checkpoint Inhibitor Resistance Using Spatial Proteomics In Metastatic Tumor Microenvironments

Immune checkpoint inhibitors have transformed cancer care, yet resistance in many metastatic patients limits their long-term success. Traditional methods fall short in revealing the complex spatial dynamics driving this resistance within the tumor microenvironment.

By leveraging cutting-edge spatial proteomics combined with deep learning-powered cell segmentation—using DNA-binding intercalators tagged with natural Iridium isotopes—this study uncovers how gene expression and protein activity vary across tumor regions. These insights reveal localized resistance mechanisms and highlight new therapeutic targets, offering a powerful window into the intricate interactions between immune cells and tumors in resistant metastatic sites.

Discover how this breakthrough approach can reshape our understanding of treatment resistance by exploring the full poster.